MNMD Archives - BioTuesdays

Developments

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...

December 16, 2024

Executive Moves

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

MindMed (NASDAQ:MNMD) has appointed Gregg Pratt, Ph.D., as chief regulatory and quality assurance officer. Dr. Pratt will oversee the company’s regulatory and quality functions, as well as its product registration...

November 18, 2024

Developments

MindMed collaborators post positive Phase 2 data with LSD in MDD

Prof. Matthias Liechti and Dr. Felix Mueller, Mind Medicine’s (NASDAQ:MNMD) collaborators at University Hospital Basel and the University Hospital of Psychiatry, released positive topline data from a double-blind...

April 14, 2023

Developments

MindMed collaborators begin dosing in Phase 1 trial of MDMA-like substances

The first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed (NASDAQ:MNMD; NEO:MMED) collaborator Prof. Dr. Matthias Liechti at University Hospital Basel to evaluate the effects of MDMA-like...

September 20, 2022

Developments

First patient dosed in MindMed GAD study with LSD

MindMed (NASDAQ:MNMD; NEO:MMED) announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of generalized...

August 29, 2022

Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022

Executive Moves

MindMed names Schond Greenway as CFO

Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...

May 24, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Developments

MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal

Mind Medicine (NASDAQ:MNMD; NEO:MMED) reported favorable safety and tolerability results from a Phase 1 placebo-controlled trial designed to assess safety, tolerability, pharmacokinetics and neurocognitive effects of MM...

May 19, 2022

Developments

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...

May 11, 2022

Tag - MNMD

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed names Gregg Pratt as chief regulatory and quality assurance officer

MindMed collaborators post positive Phase 2 data with LSD in MDD

MindMed collaborators begin dosing in Phase 1 trial of MDMA-like substances

First patient dosed in MindMed GAD study with LSD

Cantor starts MindMed at OW; PT $3

MindMed names Schond Greenway as CFO

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal

MindMed collaborators present positive Phase 2 data of LSD in anxiety

General

More